Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Clinical trial NCT02280993 · UNKNOWN
Trial details
- NCT number
- NCT02280993
- Sponsor
- Marjolein Spiering
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-01
- Primary completion
- 2018-11-01
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.